How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

801 results for

Lidocaine Patch

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

581. Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

patch test reagents (Finn chambers of 18-mm diam, Filter Discs & Scanpor tape). Before application and at several time points after removal, TEWL and erythema will be measured at the exposed site and at a control site. Erythema will be measured using a colorimeter (Minolta CR-200). Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join (...) must have TEWL of nonlesional skin of upper arm that is ≥ 8 gm/m2/h at screening visit. This is to ensure that we are in fact studying the subset of AD subjects who have a skin barrier defect. Exclusion Criteria: Unwillingness or inability to complete the Informed Consent process Subjects with a history of keloid formation History of lidocaine or Novocain allergy Subjects with a systemic infection requiring a course of systemic antibiotics or antivirals within the last 2 weeks Subjects with MD

2012 Clinical Trials

582. Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

participants will be randomly chosen to receive one of the following treatments in the study eye: A 20 μL (440 μg) intravitreal (IVT) injection of sirolimus, or A sham treatment (subconjunctival injection of lidocaine) Participants with two (2) eligible eyes will have one eye randomly assigned to receive intravitreal sirolimus and no sham in the fellow eye. The first injection will begin at Day 0, which may occur on the date of screening/enrollment or up to two weeks following screening/enrollment visit (...) participants on a quarterly basis. That is, on visits coinciding with 3 month intervals from date of enrollment. Condition or disease Intervention/treatment Phase Geographic Atrophy Drug: Sirolimus Drug: Lidocaine Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 52 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: Multi-Center

2012 Clinical Trials

583. Adrenocorticotropic Axis and Neuropathic Pain

treated only by topical treatment (lidocaine patch only for example) Pateints receiving corticosteroid treatment at the time of enrollment, or who received such treatment during the last 6 months (regardless of the dosage form and dosage), Inflammatory and evolutive pathology requiring long term treatment, Type 2 diabetes, Postmenopausal women with replacement therapy, Weight change of more than 5% within 3 months before the study, BMI <18 or> 35, Contacts and Locations Go to Information from

2012 Clinical Trials

584. Efficacy and Safety of Synera in Osteoarthritis Pain

) Primary Purpose: Treatment Official Title: Efficacy and Safety of Synera in OA Pain Study Start Date : September 2013 Actual Primary Completion Date : September 2014 Actual Study Completion Date : February 2015 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Synera lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium (...) chloride, wood flour, water and filter paper. Drug: Synera 70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours Other Name: lidocaine/tetracaine Placebo Comparator: Inactive Patch placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients. Drug: Inactive patch placebo patch applied once for 12 hours Other Name: placebo Outcome Measures Go to Primary Outcome Measures

2012 Clinical Trials

585. Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

with other antidepressants, anticonvulsants, monoamine oxidase (MAO) inhibitors, or other neuropathic pain medication agents such as carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch or gel, capsaicin cream, or amifostine; in addition, they may not be taking other agents for the treatment of neuropathy, nor other known moderate or strong CYP 2D6 (which consist of Cinacalcet [Sensipar™], quinidine, and Terbinafine [Lamisil®, Lamisil AT®]), nor the strong inducer

2012 Clinical Trials

586. Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures such as Plan B™, sold for emergency use after unprotected sex, are not acceptable methods for routine use. Patient understands the study procedures and agrees to participate in the study by giving written informed consent (Consent must be given before any study (...) , acetaminophen, lidocaine, fentanyl, atropine, and midazolam as well as latex), or has had an anaphylactic reaction or significant intolerability to a marketed or investigational prescription or non-prescription drug or to food. Patient has a history of stroke, chronic seizures, or major neurological disorder. Patient has a history of neoplastic disease. Patient is a female who is ≤8 weeks postpartum or breast feeding an infant. Patient is pregnant as determined by initial serum β-HCG obtained at Visit 1

2012 Clinical Trials

587. Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

-term central venous catheter (CVC) access to a fistula or graft access and who otherwise meet the eligibility criterial will be asked to participate. Patients will receive either a standard or an enhanced intervention to address their fear of needles. The enhanced intervention includes the standard intervention plus video training about Synera and trying out an actual patch. Over the 4 months following the intervention, how many patients sign up to switch access will be tracked. Condition (...) to make the change and/or has taken concrete steps to change behavior; and 5) Maintenance: Patient has made the behavior change and is trying maintain that change. Patients will be cluster-randomized to receive a standard needle phobia intervention (n = 32), or an enhanced intervention consisting of a standard intervention plus a demonstration of the Synera patch (n = 32) within 15 days of baseline. The intervention will be administered by a study team member. In clinics where there is more than 1

2012 Clinical Trials

588. Pharmacokinetic Study of Synera in Healthy Volunteers

: This study will measure the amount of lidocaine and tetracaine in the blood after 2-, 4-, and 12-hour application of 4 Synera patches and a 4 hour application of 4 patches without heat. Condition or disease Intervention/treatment Phase Healthy Drug: Synera Phase 1 Detailed Description: The purpose of this study was to evaluate the pharmacokinetic profiles of lidocaine and tetracaine after 2-, 4-, and 12-hour application of 4 Synera® patches and a 4-hour application of 4 lidocaine/tetracaine patches (...) without heat in healthy adult subjects and to monitor the frequency and nature of adverse events. In addition to determining the pharmacokinetics for a one-time application of 4 Synera® patches, steady-state pharmacokinetics were modeled and residual patch concentrations of lidocaine and tetracaine were determined. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 12 participants Intervention Model: Single Group Assignment Masking

2012 Clinical Trials

589. Brain Imaging of Lidoderm for Chronic Back Pain

, Northwestern University Study Details Study Description Go to Brief Summary: The investigators tested whether pain decrease can be observed centrally with non-invasive brain imaging in CBP subjects receiving Lidoderm. The investigators first tested effects of 5% Lidoderm patched in an open labelled trial. Next the investigators compared the effects of Lidocaine versus Placebo patches. Three time points were evaluated: baseline (before treatment) and 6 hours and 2 weeks after treatment. The latter trial (...) was a 2 arm, double blind, placebo controlled trial, where participants either received Lidoderm or placebo patches, without cross over. Condition or disease Intervention/treatment Phase Low Back Pain Drug: lidocaine Drug: placebo Phase 4 Detailed Description: Previous data showed that Lidoderm patches that contain 5% Lidocaine applied to the affected area for a period of 1-2 weeks decreased chronic pain. We conducted a preliminary open-label trial in chronic back pain patients and found

2012 Clinical Trials

590. Study of Possible Changes in QST After Application of Capsaicin on Patients With Peripheral Neuropathic Pain

nerve lesion, postherpetic neuralgia) and with remaining moderate pain intensity under the current treatment (> NRS 3; numeric rating scale 0-10) some remaining sensory function at the baseline QST with z-scores ≥ - 3 for cold, warmth and tactile thresholds Exclusion Criteria: with missing informed consent with any contraindications for capsaicin application with diabetes mellitus, using lidocaine patch in the test area in the last 6 months before enrollment with inadequate knowledge of the german (...) -induced changes of detection and pain thresholds based on a currently recommended standardized quantitative sensory testing (QST). The assessment of QST changes would be an important step forward to understand the way of action as well as the time course of the presumed recovering of the C-fiber function after topical application of a high concentration capsaicin patch. 10 patients suffering from peripheral neuropathic pain due to peripheral nerve injury and 10 patients suffering from postherpetic

2012 Clinical Trials

591. Synera Venipuncture Pain

, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine patch when administered for 30 ± 5 minutes to provide dermal anesthesia in adult oncology patients undergoing venipuncture as part of their care, for treatment or diagnostics (laboratory or imaging). Compared to the use of the placebo (...) patch, this study hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS Condition or disease Intervention/treatment Phase Pain Phlebotomy Palliative Care Drug: Synera (lidocaine 70mg/tetracaine 70mg) Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 61 participants Allocation: Randomized

2012 Clinical Trials

592. A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment

, methyl salicylate, local anesthetics (including patch containing lidocaine), steroids or capsaicin products on the painful areas to be treated within 7 days preceding the Baseline Visit 21. Chemotherapy within 3 months of the Baseline Visit, except maintenance hormone treatment 22. Use of any investigational agent within 30 days prior to Baseline Visit 23. Active substance abuse or history of chronic substance abuse within 1 year prior to screening; or any prior chronic substance abuse (including (...) , 2012 Actual Primary Completion Date : September 26, 2013 Actual Study Completion Date : September 26, 2013 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Qutenza Cutaneous patch Drug: Qutenza Cutaneous patch Other Name: Capsaicin Active Comparator: Pregabalin Oral capsule Drug: Pregabalin Oral capsule Outcome Measures Go to Primary Outcome Measures : Proportion of subjects in each arm who achieve

2012 Clinical Trials

593. Liver Biopsy

, position. Selective use of sedative medications during liver biopsy may alleviate anxiety 116 and appear to reduce postproce- durepain 117 ;theiruseshouldbeconsideredtobeamatter of local preference and expertise. The skin is prepped and draped, then anesthetized with a local anesthetic agent, typically lidocaine, 1%. The area from the skin to the peritoneum is also anethestized using care to advance only above the appropriate rib (in- tercostal arteries generally run below the rib so that inter- costal

2009 American Association for the Study of Liver Diseases

594. The effectiveness of drugs for neuropathic pain – what do we know?

for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as a second line treatment for lidocaine patches, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A. Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only. Neil O’Connell As well as writing for , Dr Neil O’Connell, (PhD (...) forgot to mention. The NNTs are for 50% pain reduction. If you get 30% or 40%, which is still relevant to the patient, it doesn’t count. In fact you can combine 2 drugs with 40% reduction each and your patient could do very well indeed despite not satisfying the NNT criteria for either drug. Keri says Neil, I read the above write up & I find that Capsaicin patches help with my pain. I use over the counter small dose & it helps me but what dose are you talking about when you say “High Dose

2015 Body in Mind blog

596. Overview of Coma and Impaired Consciousness

preserved until very late when coma is due to diffuse metabolic disorders (called toxic-metabolic encephalopathy), although responses may be sluggish. If one pupil is dilated, other causes of should be considered; they include past ocular trauma, certain headaches, and use of a scopolamine patch. Table Interpretation of Pupillary Response and Eye Movements Area Assessed Finding Interpretation Pupils Sluggish light reactivity retained until all other brain stem reflexes are lost Diffuse cellular cerebral (...) via rapid-sequence oral intubation (using a paralytic drug) rather than via nasotracheal intubation; nasotracheal intubation in a patient who is breathing spontaneously causes more coughing and gagging, thus increasing ICP, which is already increased because of intracranial abnormalities. To minimize the increase in ICP that may occur when the airway is manipulated, some clinicians recommend giving lidocaine 1.5 mg/kg IV 1 to 2 min before giving the paralytic. Patients are sedated before

2013 Merck Manual (19th Edition)

597. Osteoarthritis (OA)

, osteotomy, and total joint replacement should be considered if all nonsurgical approaches fail. Experimental therapies that may preserve cartilage or allow chondrocyte grafting are being studied. It is not clear whether using a topical lidocaine 5% patch relieves pain. Flavocoxid , a plant-derived compound, can be tried. Little information supports injections of platelet-rich plasma for OA. Mesenchymal stem cell therapy for cartilage repair is claimed to yield positive outcomes, especially in knee OA

2013 Merck Manual (19th Edition)

598. Neuropathic Pain

at one time ‡ Causes a severe sunburn-like skin reaction; oral opioids often required for up to 1 wk after application of capsaicin 8% to manage the worsening cutaneous pain Meaningful pain relief for 3 mo after a single application EMLA Apply tid, under occlusive dressing if possible Usually considered for a trial if a lidocaine patch is ineffective; expensive Lidocaine 5% Daily Available as patch Other Baclofen 20–60 mg bid May act via GABA B receptor Helpful in trigeminal neuralgia; used in other (...) ; adverse effects may prevent adequate analgesia. Topical drugs and a lidocaine -containing patch may be effective for peripheral syndromes. Other potentially effective treatments include Spinal cord stimulation by an electrode placed epidurally for certain types of neuropathic pain (eg, chronic leg pain after spine surgery) Electrodes implanted along peripheral nerves and ganglia for certain chronic neuralgias Sympathetic blockade, which is usually ineffective, except for some patients with complex

2013 Merck Manual (19th Edition)

599. Lichen Planus

Disorders Which of the following diagnostic tests is often done to evaluate pigmented lesions? Shaving Deep excision Patch test Scraping NEWS & VIDEOS AAD: Isotretinoin Exposure for Acne Not Linked to Depression Risk FRIDAY, March 1, 2019 (HealthDay News) -- For patients with acne, exposure to isotretinoin is not associated with an increased risk for being diagnosed with depression, according to a study... SOCIAL MEDIA Add to Any Platform Loading , MD, Harvard Medical School Click here for Patient (...) , and topical tretinoin may also be useful. As with any disease with so many therapies, individual drugs have not been uniformly successful. Apremilast (inhibitor of phosphodiesterase 4), used in treatment of psoriasis, is under study for use in women with vulvar lichen planus. Oral lichen planus Treatment of oral LP differs slightly. Viscous lidocaine may help relieve symptoms of erosive ulcers; because inflamed mucous membranes can absorb high amounts, dose should not exceed 200 mg (eg, 10 mL of a 2

2013 Merck Manual (19th Edition)

600. Treatment of Pain

% to manage the worsening cutaneous pain Meaningful pain relief for 3 mo after a single application EMLA Apply tid, under occlusive dressing if possible Usually considered for a trial if a lidocaine patch is ineffective; expensive Lidocaine 5% Daily Available as patch Other Baclofen 20–60 mg bid May act via GABA B receptor Helpful in trigeminal neuralgia; used in other types of neuropathic pain Pamidronate (injection) 60–90 mg/mo IV Evidence of efficacy in complex regional pain syndrome *Route is oral (...) unless otherwise indicated. † Newer anticonvulsants have fewer adverse effects. ‡ Topical lidocaine 4–5% applied 1 h before applying capsaicin can help limit irritation. EMLA = eutectic mixture of local anesthetics; GABA = gamma-aminobutyric acid; NMDA = N -methyl- d -aspartate. Topical drugs are also widely used. Capsaicin cream, topical NSAIDs, other compounded creams (eg, local anesthetics), and a lidocaine 5% patch have little risk of adverse effects; they should be considered for many types

2013 Merck Manual (19th Edition)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>